{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T03:27:46Z","timestamp":1763695666421,"version":"3.45.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40801-025-00499-6","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:02:25Z","timestamp":1756447345000},"page":"525-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1296-4520","authenticated-orcid":false,"given":"Sicily","family":"Mburu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6468-0397","authenticated-orcid":false,"given":"George C.","family":"Gondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Kornyeyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Frade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"499_CR1","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.amjmed.2018.05.013","volume":"131","author":"J Bilal","year":"2018","unstructured":"Bilal J, Malik SU, Riaz IB, Kurtzman DJB. Psoriasis and psoriatic spectrum disease: a primer for the primary care physician. Am J Med. 2018;131:1146\u201354.","journal-title":"Am J Med"},{"key":"499_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80:1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"key":"499_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052935","volume":"7","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003\u20132011. PLoS\u00a0One. 2012;7: e52935.","journal-title":"PLoS\u00a0One"},{"key":"499_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2310\/7750.2008.07060","volume":"12","author":"AK Gupta","year":"2008","unstructured":"Gupta AK, Langley RG, Lynde C, Barber K, Gulliver W, Lauzon G, et al. ISA247: quality of life results from a phase II, randomized, placebo-controlled study. J Cutan Med Surg. 2008;12:268\u201375.","journal-title":"J Cutan Med Surg"},{"key":"499_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/acr.23896","volume":"72","author":"D Sumpton","year":"2020","unstructured":"Sumpton D, Kelly A, Tunnicliffe DJ, Craig JC, Hassett G, Chessman D, et al. Patients\u2019 perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies. Arthritis Care Res (Hoboken). 2020;72:711\u201322.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"499_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13555-022-00846-3","volume":"13","author":"J Koren","year":"2023","unstructured":"Koren J, Lambert JLW, Thomsen SF, McAteer H, Fabbrocini G, Corazza V, et al. Elevating the standard of care for patients with psoriasis: \u2018calls to action\u2019 from Epicensus, a multistakeholder pan-European initiative. Dermatol Ther (Heidelb). 2023;13:245\u201368.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"499_CR7","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/jdv.15065","volume":"32","author":"A Armstrong","year":"2018","unstructured":"Armstrong A, Jarvis S, Boehncke WH, Rajagopalan M, Fern\u00e1ndez-Pe\u00f1as P, Romiti R, et al. Patient perceptions of clear\/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018;32:2200\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"499_CR8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157:940\u20136.","journal-title":"JAMA Dermatol"},{"key":"499_CR9","first-page":"16","volume":"7","author":"AF Alexis","year":"2014","unstructured":"Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014;7:16\u201324.","journal-title":"J Clin Aesthet Dermatol."},{"key":"499_CR10","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945\u201360.","journal-title":"JAMA"},{"key":"499_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"499_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","volume":"27","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27:118\u201326.","journal-title":"Curr Opin Rheumatol"},{"key":"499_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, Khraishi MM, Tha\u00e7i D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"499_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3899\/jrheum.140474","volume":"42","author":"R Ranza","year":"2015","unstructured":"Ranza R, Carneiro S, Qureshi AA, Martins G, Rodrigues JJ, Romiti R, et al. Prevalence of psoriatic arthritis in a large cohort of Brazilian patients with psoriasis. J Rheumatol. 2015;42:829\u201334.","journal-title":"J Rheumatol"},{"key":"499_CR15","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/art.39494","volume":"68","author":"L Eder","year":"2016","unstructured":"Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 2016;68:915\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"499_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.737256","volume":"8","author":"AYT Chia","year":"2021","unstructured":"Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing psoriatic arthritis with inflammatory bowel disease and\/or uveitis. Front Med (Lausanne). 2021;8: 737256.","journal-title":"Front Med (Lausanne)."},{"key":"499_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/rheumatology\/kez202","volume":"59","author":"JZ Fei","year":"2020","unstructured":"Fei JZ, Perruccio AV, Ye JY, Gladman DD, Chandran V. The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. Rheumatology (Oxford). 2020;59:69\u201376.","journal-title":"Rheumatology (Oxford)"},{"key":"499_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","volume":"17","author":"MG Lebwohl","year":"2016","unstructured":"Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17:87\u201397.","journal-title":"Am J Clin Dermatol"},{"key":"499_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15759","volume":"35","author":"F Diotallevi","year":"2022","unstructured":"Diotallevi F, Paolinelli M, Radi G, Offidani A. Latest combination therapies in psoriasis: narrative review of the literature. Dermatol Ther. 2022;35: e15759.","journal-title":"Dermatol Ther"},{"key":"499_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Am Acad Dermatol. 2014;70:871\u201381.","journal-title":"J Am Acad Dermatol"},{"key":"499_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/18734316MTA35NzY65","volume":"22","author":"G Radi","year":"2021","unstructured":"Radi G, Campanati A, Diotallevi F, Bianchelli T, Offidani A. Novel therapeutic approaches and targets for treatment of psoriasis. Curr Pharm Biotechnol. 2021;22:7\u201331.","journal-title":"Curr Pharm Biotechnol"},{"issue":"Suppl 1","key":"499_CR22","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","volume":"59","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59(Suppl 1):i37-46.","journal-title":"Rheumatology (Oxford)"},{"key":"499_CR23","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3899\/jrheum.201195","volume":"48","author":"DD Gladman","year":"2021","unstructured":"Gladman DD, Starr M, Cividino A, Gaudreau AJ, Jelley J, Nicholson D, et al. Canadian rheumatologists\u2019 perspectives on moderate psoriatic arthritis and oligoarticular psoriatic arthritis. J Rheumatol. 2021;48:1692\u20137.","journal-title":"J Rheumatol"},{"key":"499_CR24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/bjd.15574","volume":"177","author":"PA Nelson","year":"2017","unstructured":"Nelson PA, Kane K, Pearce CJ, Bundy C, Chisholm A, Hilton R, et al. \u2018New to me\u2019: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well\u00ae patient materials mixed-methods feasibility study. Br J Dermatol. 2017;177:758\u201370.","journal-title":"Br J Dermatol"},{"key":"499_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13555-022-00695-0","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Bohannan B, Mburu S, Alarcon I, Kasparek T, Toumi J, et al. Impact of psoriatic disease on quality of life: interim results of a global survey. Dermatol Ther (Heidelb). 2022;12:1055\u201364.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"499_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1159\/000528945","volume":"239","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Bohannan B, Mburu S, Coates LC, Ogdie A, Alarcon I, et al. Patient perspectives on psoriatic disease burden: results from the global Psoriasis and Beyond survey. Dermatology. 2023;239:621\u201334.","journal-title":"Dermatology"},{"key":"499_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"499_CR28","first-page":"469","volume":"27","author":"GH Ibrahim","year":"2009","unstructured":"Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27:469\u201374.","journal-title":"Clin Exp Rheumatol"},{"key":"499_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005;125:659\u201364.","journal-title":"J Invest Dermatol"},{"key":"499_CR30","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","volume":"42","author":"D Kane","year":"2003","unstructured":"Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"499_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-015-0652-z","volume":"17","author":"A Mc Ardle","year":"2015","unstructured":"Mc Ardle A, Flatley B, Pennington SR, FitzGerald O. Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. Arthritis Res Ther. 2015;17:141.","journal-title":"Arthritis Res Ther"},{"key":"499_CR32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045\u201350.","journal-title":"Ann Rheum Dis"},{"key":"499_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/13696998.2018.1557201","volume":"22","author":"D Pilon","year":"2019","unstructured":"Pilon D, Teeple A, Zhdanava M, Ladouceur M, Ching Cheung H, Muser E, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22:196\u2013203.","journal-title":"J Med Econ"},{"key":"499_CR34","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1365-4632.2011.05359.x","volume":"51","author":"AR Levy","year":"2012","unstructured":"Levy AR, Davie AM, Brazier NC, Jivraj F, Albrecht LE, Gratton D, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51:1432\u201340.","journal-title":"Int J Dermatol"},{"key":"499_CR35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bjd.18798","volume":"183","author":"R Villacorta","year":"2020","unstructured":"Villacorta R, Teeple A, Lee S, Fakharzadeh S, Lucas J, McElligott S. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183:548\u201358.","journal-title":"Br J Dermatol"},{"key":"499_CR36","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000093848","volume":"213","author":"JM Schmitt","year":"2006","unstructured":"Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213:102\u201310.","journal-title":"Dermatology"},{"key":"499_CR37","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jaad.2023.03.039","volume":"89","author":"D Yee","year":"2023","unstructured":"Yee D, Kingston P, Lee K, Huang M, Peterson H, Korouri E, et al. Shared decision-making and satisfaction with care in psoriasis patients: a population-based study in the United States. J Am Acad Dermatol. 2023;89:920\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"499_CR38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jaad.2020.01.045","volume":"83","author":"P Singh","year":"2020","unstructured":"Singh P, Silverberg JI. Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol. 2020;83:256\u20137.","journal-title":"J Am Acad Dermatol"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00499-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:17:01Z","timestamp":1763687821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00499-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["499"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00499-6","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"12 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study, medical writing support, and open access fee for this manuscript were funded by Novartis AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.W.A. has served as a research investigator, scientific advisor, and\/or speaker at AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, LEO Pharma, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer. S.M. receives no individual compensation and is employed by IFPA. In the past 12 months, IFPA has accepted grants and funding from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, Leo Pharma, Eli Lilly, Novartis, Pfizer, and UCB. G.C.G. is an employee of The National Psoriasis Foundation. E.K. was a full-time employee of Novartis Pharma AG, Basel, Switzerland. S.F. is a full-time employee of Novartis Pharma AG, Basel, Switzerland. A.O. serves as a consultant of AbbVie, Amgen, BMS, Celgene, CorEvitas, Eli Lilly, GSK, Gilead, Janssen, Merck, Novartis, Pfizer, Spyre Therapeutics, Takeda, Treg Therapeutics, and UCB Pharma and has received grants and\/or research support from AbbVie, Amgen, BMS, Janssen, Novartis, Pfizer, UCB, Forward\/National Databank for Rheumatic Diseases, NIH\/NIAMS, PPACMAN, Rheumatology Research Foundation, and The National Psoriasis Foundation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Results analyzed during this study are included in this published article and its supplementary information files; additional data may be available upon request from Novartis on a case-by-case basis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"An institutional review board (Pearl IRB) considered this study to be exempt from ethics approval according to FDA 21 CFR 56.104 and 45CFR46.104(b)(2):(2).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed digital consent was obtained from patients before study participation. The procedure for obtaining electronic informed consent was outlined in the Psoriasis and Beyond study protocol, which was reviewed and approved according to local laws and regulations.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"A.W.A., A.O., S.F., and S.M.: study conception and design, data interpretation, and writing\/revision of the manuscript. E.K. and G.C.G.: data interpretation and writing\/revision of the manuscript. All authors reviewed and approved the final version of the manuscript for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}